KC-5490

U87MG-ERBB2-Luc2 Cell Line

×
56654
Home » U87MG-ERBB2-Luc2 Cell Line

Background of U87MG-ERBB2-Luc2 Cell Line

ERBB2 encodes erb-b2 receptor tyrosine kinase 2 and is also known as NEU. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

Specifications

Catalog NumberKC-5490
Cell Line NameU87MG-ERBB2-Luc2 Cell Line
Clone Number8#
Host Cell LineU87MG-Luc2
DescriptionU87MG-ERBB2-Luc2 is a stable engineered cell line expressing human ERBB2-Luc2
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% (MEM+20% FBS+10% DMSO
Propagation Medium(MEM+0.01mM NEAA)+10%FBS+1%Sodium pyruvate+2μg/mL puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit at a ratio of 1:4–1:6 every 2–3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 19–36 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

U87MG-ERBB2-Luc2 cell line was generated using a lentiviral vector expressing the human ERBB2-Luc2 sequence.

Characterization

Figure 1: Characterization of ERBB2 overexpressing in U87MG-Luc2-ERBB2 stable clones using FACS.

Figure 2. Characterization of U87MG-Luc2-ERBB2 cell line stable clone using Bright-Glo Detection System in the conditions of different cell number.

Figure3: Characterization of U87MG-Luc2-ERBB2 cell line stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4–1:6 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Dean L, Kane M Pertuzumab Therapy and ERBB2 Genotype. . 2012;:. PMID: 28520364.
  2. Dean L, Kane M Trastuzumab Therapy and ERBB2 Genotype. . 2012;:. PMID: 28520362.
  3. Kashizaki F, Orii R, Watanabe S et al. Clinical Efficacy of HER2-targeted Monotherapy in ERBB2-mutant Non-Small-Cell Lung Cancer: A Systematic Review and Single-arm Meta-Analysis. Clinical lung cancer. 2026 Jun;27(5):55-64.e6. PMID: 42070909. doi: 10.1016/j.cllc.2026.03.018.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.